The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial - Full Text View

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00799903

Purpose

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.

Condition	Intervention	Phase
CV Risk Atherosclerosis Cardiovascular Disease Coronary Heart Disease	Drug: Darapladib Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis Coronary Artery Disease Heart Attack Heart Diseases

Drug Information available for: Darapladib

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Time to the first occurrence of any component of the composite of Major Adverse Cardiovascular Events [MACE: CV death (death due to a cardiovasacular cause), non-fatal myocardial infarction, non-fatal stroke] [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The composite measure of major coronary events that include the time to first occurrence of coronary heart disease death, non-fatal myocardial infarction or urgent coronary revascularization for myocardial ischemia [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]
The composite measure of total coronary events that include the time to first occurrence of coronary heart disease death, non-fatal myocardial infarction, hospitalization for unstable angina , or any coronary revascularization procedure [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]
The time to individual components of MACE [cardiovascular death, myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal) ] [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]
The time to the first occurrence of any component of the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]
All cause mortality [ Time Frame: Patients will remain in the study until a specified number of MACE events have occurred. It is anticipated that patients will be in the study about 3 years. ] [ Designated as safety issue: No ]

Enrollment:	15828
Study Start Date:	December 2008
Estimated Study Completion Date:	August 2013
Estimated Primary Completion Date:	August 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Darapladib Single daily oral tablet	Drug: Darapladib Lp-PLA2 inhibitor administered in addition to standard therapy
Placebo Comparator: Placebo Single daily oral tablet	Drug: Placebo Placebo administered in addition to standard therapy

Detailed Description:

Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, and every 6 months until the end of the study. Average time in the study for an individual subject is expected to be about 3 years.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men or women at least 18 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject.
Chronic coronary heart disease
At least one of the following:
At least 60 years old
Diabetes requiring treatment with medication
Low HDL cholesterol ("good cholesterol")
Currently smoke cigarettes or stopped smoking within the past 3 months
Diagnosed mild or moderate reduction in kidney function
Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease.

Exclusion Criteria:

Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure.
Liver disease
Severe reduction in kidney function OR removal of a kidney OR kidney transplant
Severe heart failure
Blood pressure higher than normal despite lifestyle changes and treatment with medications
Any life-threatening disease expected to result in death within the next 2 years (other than heart disease)
Severe asthma that is poorly controlled with medication
Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to study entry)
Previous severe allergic response to food, drink, insect stings, etc.
Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
Certain medications that may interfere with the study medication (these will be identified by the study doctor)
Participation in a study of an investigational medication within the past 30 days
Current participation in a study of an investigational device

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00799903

Show 641 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier:	NCT00799903 History of Changes
Other Study ID Numbers:	100601
Study First Received:	November 26, 2008
Last Updated:	January 26, 2012
Health Authority:	Estonia: State Agency of Medicines; Chile: Institutional Review Board; Brazil: Institutional Review Board; Peru: Institutional Review Board; Czech Republic: Státní ústav pro kontrolu léčiv, Oddělení klinického hodnocení; Spain: Agencia Española del Medicamento y Productos Sanitarios; United Kingdom: Medicines and Healthcare Products Regulatory Agency; Italy: Comitato Etico Unico per la Provincia di Parma; Bulgaria: The Bulgarian Drug Agency; Argentina: Ministry of Health - A.N.M.A.T; Belgium: Agence Fédérale des Médicaments et des Produits de la Santé; Romania: Agentia Nationala a Medicamentului; Pakistan: Drug Controller R&D Ministry of Health; Norway: Statens Legemiddelverk; Denmark: Lægemiddelstyrelsen; Philippines: Bureau of Food and Drugs; Hungary: Országos Gyógyszerészeti Intézet; South Africa: Medicines Control Council; Slovak Republic: Štátny ústav pre kontrolu liečiv; Poland: URZ.D REJESTRACJI PRODUKTÓW LECZNICZYCH, WYROBÓW MEDYCZNYCH I PRODUKTÓW BIOBÓJCZYCH,CEBK; Canada: Health Canada; Germany: Bundesinstitut für Arzneimittel und Medizinprodukte; France: Agence Française de Sécurité Sanitaire des Produits de Santé; Netherlands: De Centrale Commissie Mensgebonden Onderzoek; China: State Food and Drug Administration; South Korea: Food and Drug Administration; United States: Food and Drug Administration; Sweden: Läkemedelsverket; Greece: National Drug Organisation

Keywords provided by GlaxoSmithKline:

heart disease
Lp-PLA2 inhibitor
cardiovascular disease
coronary heart disease
Atherosclerosis

Additional relevant MeSH terms:

Atherosclerosis
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases

Plaque, Atherosclerotic
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on February 09, 2012